NCT01441804

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Third Affiliated Hospital, Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 16 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Patients with HCV genotype 1 and IL28B CC Polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	Peginterferon alfa2a	patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
DRUG	Ribavirin	patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
DRUG	Peginterferon alfa2a	patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
DRUG	Ribavirin	patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks

Timeline

• Start date: 2011-05-01
• Primary completion: 2014-05-01
• Completion: 2014-08-01
• First posted: 2011-09-28
• Last updated: 2013-10-01

Locations

4 sites across 1 country: China